Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma.
Nicolas Thomas IannozziValentina MarchicaDenise ToscaniJessica Burroughs GarcìaNicola GiulianiPaola StortiPublished in: International journal of molecular sciences (2022)
Multiple myeloma (MM) is a monoclonal gammopathy characterized by biological heterogeneity and unregulated proliferation of plasma cells (PCs) in bone marrow (BM). MM is a multistep process based on genomic instability, epigenetic dysregulation and a tight cross-talk with the BM microenvironment that plays a pivotal role supporting the proliferation, survival, drug-resistance and homing of PCs. The BM microenvironment consists of a hematopoietic and a non-hematopoietic compartment, which cooperate to create a tumor environment. Among the non-hematopoietic component, mesenchymal stromal cells (MSCs) and osteoblasts (OBs) appear transcriptionally and functionally different in MM patients compared to healthy donors (HDs) and to patients with pre-malignant monoclonal gammopathies. Alterations of both MSCs and OBs underly the osteolytic lesions that characterize myeloma-associated bone disease. In this review, we will discuss the different characteristics of MSCs and OBs in MM patients, analyzing the transcriptome, the deregulated molecular pathways and the role performed by miRNAs and exosome in the pathophysiology of MM.
Keyphrases
- bone marrow
- multiple myeloma
- mesenchymal stem cells
- end stage renal disease
- newly diagnosed
- induced apoptosis
- stem cells
- ejection fraction
- signaling pathway
- chronic kidney disease
- peritoneal dialysis
- gene expression
- cell cycle arrest
- dna methylation
- oxidative stress
- single cell
- blood brain barrier
- umbilical cord
- rna seq
- cell death
- angiotensin ii
- free survival
- cell proliferation